Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

Completed · Phase 2 · Has a placebo group

Conditions studied: Hepatobiliary Disorders, Non-alcoholic Steatohepatitis

In brief

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis

Key facts

Study ID
NCT02970942
Run by
Novo Nordisk A/S
People needed
320
Starts
2016-11-30
Expected to finish
2020-03-19
Last updated by the study team
2021-11-16

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.